ClinicalTrials.gg
RecruitingNCT07229352Updated Nov 5, 2026

Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses

An interventional study of Novel spectacle lens design and Spectacle lenses in Myopia, Myopia Progression and Juvenile Myopia, sponsored by SightGlass Vision, Inc.. Recruiting at 1 site in United States. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by SightGlass Vision, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 5, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Myopia by SightGlass Vision, Inc. — 3 open to participants now, 12 under way, none of them phase 3. Myopia · SightGlass Vision, Inc..

Planned enrollment
10th of 14
40 · median 71
Started
2026
the only one that year
No phase
14 of 14
3 open now
Primary completion
2027-12
later than 11 of 11 live
Registered
13th of 14
by date

Among the 14 studies in Myopia by SightGlass Vision, Inc., this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 14 with no phase, reaches primary completion later than 11 of the 11 other live ones, and was the 13th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

3 of the 14 studies in Myopia by SightGlass Vision, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Myopia by SightGlass Vision, Inc., or all of them as a file.
02

Study summary

The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing standard single vision spectacle lenses and myopia control spectacle lenses.

03

Conditions studied

  • Myopia
  • Myopia Progression
  • Juvenile Myopia

Browse trials for

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A participant is eligible for inclusion in the study if they meet the following criteria:

  • Are between the ages of 6 and 12 years of age (inclusive) at the time of /assent.
  • Can achieve a corrected visual acuity of 20/20 best-corrected (or equivalent logMAR).
  • Have undergone a self-reported oculo-visual examination within the past two years.
  • Have no active ocular disease.
  • Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.
  • Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.
  • The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.

Exclusion criteria

Exclusion Criteria:

A participant will be excluded from the study if they meet any of the following conditions:

  • Have any systemic disease that affects ocular health.
  • Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.
  • Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.
  • Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.
  • Have known developmental delays.
  • Have participated in another clinical study in the last 7 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    SightGlass Vision Test Arm 1

    Single vision, impact-resistant spectacle lenses

    Device: Novel spectacle lens design

  • Active comparator
    Control Arm

    Single vision, impact-resistant spectacle lenses

    Device: Spectacle lenses

Interventions

  • DeviceNovel spectacle lens design

    Use of lenses to correct myopia and may reduce the rate of progression of juvenile myopia

  • DeviceSpectacle lenses

    Use of lenses to correct myopia and may reduce the rate of progression of juvenile myopia

06

What researchers measure

Primary outcomes

  1. Reaction time: the time elapsed between the appearance or activation of a visual stimulus and the initiation of the participant's physical response

    Time frame: 2 months

  2. Movement time: the time taken to complete the motor response after it has been initiated.

    Time frame: 2 months

  3. Response accuracy: the correctness of the participant's response to each visual stimulus, measured by the number or percentage of correctly identified or responded-to stimuli.

    Time frame: 2 months

Secondary outcomes

  1. Gait cycle events, such as initial foot contact with the ground and toe-off. It will be used to assess whether the type of eyewear affects natural gait patterns or mobility during peripheral vision tasks.

    Time frame: 2 months

07

Study locations

1 of 1 sites recruiting
  • Midwestern University Arizona College of Optometry
    Glendale, Arizona 85308, United States
    Recruiting
    • Javier Gantes-Nunez · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 22 months is above that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Dec 2027 and completion Jul 2027 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2025
First posted
Nov 17, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Jul 1, 2028was Jul 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2027
Nov 5, 2026
Study completion
Jul 1, 2027→Jul 1, 2028
Nov 5, 2026
Enrollment
20→40
Nov 5, 2026
Interventions
Arm changed SightGlass Vision Test Arm 2→Control Arm
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 31, 2026→Dec 31, 2027
    Study completion Jul 1, 2027→Jul 1, 2028
    Enrollment 20→40
    Interventions Arm changed SightGlass Vision Test Arm 2→Control Arm
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07229352
Lead sponsor
SightGlass Vision, Inc.
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Feb 2, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Jennifer Hill
Contact
jhill@sightglassvision.com
6783614877

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion